Aprataxin Tumor Levels Predict Response of Colorectal Cancer Patients to Irinotecan-based Treatment

Abstract

These results show that aprataxin tumor levels can be used to identify patients with low probability of response to irinotecan-based therapy who are ideal candidates to receive treatment with alternative agents in an attempt to improve patient survival.